Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.5 (EPT/RI)-Alliance Pharma plc

13 Jan 2025 09:02

Form 8.5 (EPT/RI)-Alliance Pharma plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlliance Pharma plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is financial advisor to Aegros Bidco Limited (a newly incorporated company indirectly owned by DBAY Affiliates and the ERES IV Fund)
(d) Date dealing undertaken:10th January 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
Ordinary sharesPurchases3,631,97261.260.8
Ordinary sharesSales3,679,32061.361

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
N/AN/AN/AN/AN/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
N/AN/AN/AN/AN/AN/AN/AN/A

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
N/AN/AN/AN/AN/A

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
N/AN/AN/AN/A

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:13th January 2025
Contact name:Priyali Bhattacharjee
Telephone number:+91 9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
1st Dec 20177:00 amRNSAcquisition of AmetopT
17th Oct 20179:14 amRNSHardman Research: Kelo-cote international sales
13th Sep 20177:00 amRNSInterim Results
6th Sep 20177:00 amRNSAppointment of Joint Corporate Broker
1st Aug 20177:00 amRNSNotification of Interim Results
28th Jul 20174:21 pmRNSUpdate on Diclectin
25th Jul 20175:40 pmRNSChanges to interests of a significant shareholder
25th Jul 20175:34 pmRNSChanges to interests of a significant shareholder
18th Jul 20177:00 amRNSHalf Year Trading Update
3rd Jul 20172:29 pmRNSChanges to interests of a significant shareholder
26th Jun 20175:31 pmRNSChanges to interests of a significant shareholder
22nd Jun 20175:22 pmRNSChanges to interests of a significant shareholder
21st Jun 20172:53 pmRNSApplication for block admission
19th Jun 20173:16 pmRNSChanges to interests of a significant shareholder
19th Jun 20172:37 pmRNSApplication for admission
14th Jun 20174:54 pmRNSApplication for admission
25th May 20173:20 pmRNSChanges to interests of a significant shareholder
25th May 201711:00 amRNSResult of AGM
25th May 20177:15 amRNSHardman Res.: Transformed International Business
25th May 20177:00 amRNSAGM Statement
22nd May 201710:10 amRNSApplication for admission
9th May 20171:50 pmRNSCorrection: Application for admission
8th May 20172:30 pmRNSApplication for admission
5th May 20176:10 pmRNSApplication for admission
5th May 20177:00 amRNSChanges to interests of a significant shareholder
5th May 20177:00 amRNSChanges to interests of a significant shareholder
4th May 20171:30 pmRNSChanges to interests of a significant shareholder
28th Apr 201712:15 pmRNSAnnual Report and AGM Notice
28th Apr 20179:45 amRNSChanges to interests of a significant shareholder
24th Apr 201711:33 amRNSChanges to interests of a significant shareholder
5th Apr 20171:30 pmRNSNotification of Major Interest in Shares
31st Mar 20174:59 pmRNSApplication for admission
29th Mar 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
2nd Mar 20177:00 amRNSNotification of Preliminary Results
14th Feb 20175:31 pmRNSPDMR shareholding
14th Feb 20175:30 pmRNSApplication for admission
7th Feb 20179:05 amRNSChanges to interests of a significant shareholder
31st Jan 20177:00 amRNSExercise of Share Options
25th Jan 20177:15 amRNSHardman Research: Potential of Diclectin
23rd Jan 20177:00 amRNSPre-Close Trading Update
16th Dec 20164:00 pmRNSExercise of Share Options
15th Dec 20164:50 pmRNSExercise of Share Options
12th Dec 20169:19 amRNSExercise of Share Options
9th Dec 201611:45 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20167:00 amRNSCapital Markets Event
30th Nov 20164:00 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.